Sulfonylurea

Minimizing hypoglycemia in type 2 diabetes patients…. Hypoglycemia is a common problem among patients taking combinations of insulin and sulfonylureas and may be a limiting factor in diabetes therapy management. Hypoglycemia is defined by the American Diabetes Association (ADA) as a plasma glucose of 79mg/dL. (3.9mmol/L) or less; however most people …

New research assesses safety and efficacy of linagliptin as add on treatment in elderly diabetes patients….

Does Bydureon once weekly show benefit in type 2 diabetic patients?…

Scientific understanding of the disease shifts treatment to drugs with newer mechanisms…. 

About 50% of patients experience the dawn phenomenon…. 

In earlier clinical trials dapagliflozin consistently reduced HbA1c in treatment-naive patients….

Dr. Cyrus Desouza, MBBS, reveals the dark secret behind why patients still use sulfonylureas. Although very effective inititally, the drug is only effective for a limited amount of time and there is beta cell burnout. Dr. Desouza tries not to start patients on sulfonylureas as a second-line; instead he’d rather start with basal …

The risk of ischemic events may be higher with a specific subclass of sulfonylureas…. 

Data from a large retrospective cohort study suggested that, diabetic patients treated with three commonly prescribed sulfonylurea drugs had a 50% higher mortality risk compared with patients treated with metformin…. 

The ACP has issued a clinical practice guideline regarding use of oral agents in type 2 diabetes entitled, “Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians.”… This is important because despite new therapies, there hasn’t been a guideline from either …